{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-008110","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.086172+00:00","generated_at":"2026-06-25T21:29:48.934243+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Omeros Q1 net loss $33.0M ($0.53/shr); OMIDRIA royalties $13.8M; preparing FDA dispute resolution","bullets":["Net loss of $33.0M ($0.53/shr) vs $35.1M ($0.57) in Q1 2021; non-cash items $4.2M.","Royalty revenue of $13.8M from Rayner's OMIDRIA sales ($27.7M, all U.S.); up from $21.1M prior Omeros net sales.","Cash, equivalents, short-term investments $142.2M at March 31, 2022; down $15M from Dec 2021.","FDA denied narsoplimab BLA (TA-TMA); Omeros plans formal dispute resolution within weeks.","Enrollment expected summer 2022 for Phase 1b OMS906 (PNH) and Phase 1 OMS1029 (long-acting MASP-2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-008110","json":"https://secwatch.observer/filing/0001558370-22-008110.json","markdown":"https://secwatch.observer/filing/0001558370-22-008110.md","text":"https://secwatch.observer/filing/0001558370-22-008110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022008110/0001558370-22-008110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837022008110/omer-20220510x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:29:48.934243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}